Analyst rates ADTRAN a Hold with a $5.40 target: optical growth alone cannot justify a higher multiple without margin and ...
Analyst rates Prenetics Global a Buy: its $13.30 FY 2027 target implies 29% upside; IM8 may generate 3:1 gross profit on ...
The bull case for Yellow Cake: its shares trade at a 30% discount to NAV, offering uranium exposure as nuclear capacity ...
Analyst rates Atlas Copco a Hold: a 40% valuation premium at 30.8x earnings could limit returns and expose shares to declines ...
Analyst rates BTQ Technologies a Sell: after five revenue-free quarters, 2.3 quarters of cash mean one year of burn could ...
Analyst sees BlackRock as a better franchise, yet $1,101.72 leaves little cushion for lower profits; $63.30 2027 EPS supports ...
The bull case for Zimmer Biomet: at 9.66x forward EV/EBITDA, its transformation could drive share gains as China headwinds ...
Analyst sees QQQ as near fair value: a base DCF values the Nasdaq-100 at 22,679, 9% below its close, with no margin of safety ...
Analyst rates Edgewise Therapeutics a speculative Buy with a ~$59 target, about 40% upside from $42, as cash supports a ...
The largest commercial development remains the October 1 SpaceX order for $68.1 million, or £51.3 million, of Cerus E-band ...
Simmons First National Corporation (SFNC) is downgraded from 'buy' to 'hold' as valuation rises and asset quality ...
Analyst sees EGGY as a tactical rebound play; its 25% target distribution likely erodes NAV unless holdings rebound sharply.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results